Rhythmone SR Release Capsule 225 mg (Propafenone Hydrochloride)

Adult dose

The dose of this medicine should be adjusted according to each patient's response and tolerability. Individual titration of the maintenance dose must be strictly managed by a cardiologist under cardiac monitoring, including electrocardiogram (ECG) monitoring and repeated blood pressure measurements. This medicine may be taken with or without food. This medicine, or its contents, should be swallowed whole with water. Do not chew or crush the contents of this medicine. Adults: The initial dose is 225mg per dose twice daily, every 12 hours. After at least 5 days of treatment, the dose may be increased to 325mg per dose twice daily. If additional therapeutic effect is needed, after at least 5 more days of treatment, the dose may be increased to 425mg per dose every 12 hours. Dose reduction should be considered in patients who develop significant widening of the QRS complex or second- or third-degree atrioventricular block.

This medication is used to treat cardiac arrhythmias; however, it may be risky for patients who have recently suffered a myocardial infarction or have structural heart problems. Particularly, it should not be administered to patients with significantly impaired heart function or specific cardiac diseases. Additionally, patients with allergies to this medication or conditions such as specific cardiac conduction disorders, severe bradycardia, severe hypotension, etc., should not use this medication. Patients with impaired kidney or liver function, elderly patients, and those with asthma need special caution when using this medication, and regular monitoring of ECG and blood pressure during treatment is essential. This medication may interact with other drugs, so caution is warranted when used with drugs metabolized in the liver or those affecting the heart. Pregnant women should closely monitor the status of the fetus and newborn when using this medication, and it is advisable to avoid use during breastfeeding or to discontinue breastfeeding. The safety for children has not been established and is not recommended; elderly patients should start at a low dose and be closely monitored. In the case of overdose, severe cardiac problems and central nervous system symptoms may occur, necessitating immediate emergency treatment. Finally, this medication should be stored out of reach of children, and care should be taken not to transfer it to another container.

Thrombocytopenia, agranulocytosis, leukopenia, neutropenia, hypersensitivity, decreased appetite, anxiety, sleep disturbances, nightmares, confusion, dizziness, headache, taste disorder, syncope, ataxia, sensory disturbances, seizures, extrapyramidal symptoms, anxiety, visual disturbances, drowsiness, dizziness, heart conduction disturbance, palpitations, sinus bradycardia, bradycardia, tachycardia, atrial flutter, ventricular tachycardia, arrhythmia, ventricular fibrillation, heart failure, decreased heart rate, hypotension, orthostatic hypotension, dyspnea, abdominal pain, vomiting, nausea, diarrhea, constipation, thirst, abdominal distension, bloating, nausea, abnormal liver function, hepatocyte damage, cholestasis, hepatitis, jaundice, urticaria, pruritus, rash, erythema, acute generalized exanthematous pustulosis, lupus syndrome, erectile dysfunction, decreased sperm count, chest pain, lethargy, fatigue, fever

This medication may be sensitive to air or moisture, so it should be stored in a tightly sealed container. It is best to maintain a storage temperature between 1 and 30 degrees Celsius. Avoid storing in excessively hot or cold places.

Appearance

A white to almost white, opaque hard capsule containing round, biconvex, sustained-release microtablets.

Package unit

50 capsules (10 capsules/PTP x 5)